Skip to content

Clinical trials

Bronchiolitis Obliterans Syndrome trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Bronchiolitis Obliterans Syndrome Country / region: China Clear all

50 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20092
20124
20133
20141
20151
20161
20172
20182
20192
20203
20214
20223
20232
20245
202510
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting15
Completed14
Unknown status11
Active, not recruiting6
Terminated2
Not yet recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals6
Sanofi3
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine3
Ausper Biopharma Co., Ltd.2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
First Affiliated Hospital of Zhejiang University2
Nanfang Hospital, Southern Medical University2
Wenzhou Medical University2
Beijing Ditan Hospital1
Beijing InnoCare Pharma Tech Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Bronchiolitis Obliterans Syndrome50
Hepatitis B5
Uremia5
Graft vs Host Disease4
Leukemia3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive3
Lymphoma, Follicular3
Hematologic Neoplasms2
Hepatitis B, Chronic2
Lymphoma, Large B-Cell, Diffuse2

Trials

Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.